France childhood vaccine schedule: 10 vaccines by age
For babies (first year): Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR, Meningococcal. Click a vaccine for its France-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| Hepatitis B · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 11 months |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 11 months Booster — 6 years Booster — 11-13 years |
| Polio (IPV) · side effects & data | Universal | Dose 1 — 2 months (IPV) Dose 2 — 4 months (IPV) Dose 3 — 11 months (IPV) Booster — 6 years (IPV) Booster — 11-13 years (IPV) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 11 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 11 months |
| Rotavirus · side effects & data | Selective / risk-based | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months |
| MMR · side effects & data | Universal | Dose 1 — 12 months (MMR) Dose 2 — 16-18 months (MMR) |
| Meningococcal · side effects & data | Universal | MenB dose 1 — 3 months (MenB then MenACWY) MenB dose 2 — 5 months (MenB then MenACWY) MenB booster — 12 months (MenB then MenACWY) MenACWY — 11-13 years (MenB then MenACWY) |
| HPV · side effects & data | Universal | Dose 1 — 11-14 years Dose 2 — 5-13 months after dose 1 |
| Influenza (flu) · side effects & data | Selective / risk-based | Annual — Risk groups, 65+ and pregnancy |
France vaccine schedule vs. the United States
France and the United States share 10 routine vaccines. The U.S. routinely gives Varicella (chickenpox), Hepatitis A, COVID-19, which France does not.
| Vaccine | France first dose | U.S. first dose | Doses |
|---|---|---|---|
| Hepatitis B | 2 months | Birth | 3 vs 3 doses |
| DTaP / Tdap | 2 months | 2 months | 5 vs 5 doses |
| Polio (IPV) | 2 months | 2 months | 5 vs 4 doses |
| Hib | 2 months | 2 months | 3 vs 4 doses |
| Pneumococcal (PCV) | 2 months | 2 months | 3 vs 4 doses |
| Rotavirus | 2 months | 2 months | 3 vs 3 doses |
| MMR | 12 months | 12-15 months | 2 vs 2 doses |
| Meningococcal | 3 months | 11-12 years | 4 vs 2 doses |
| HPV | 11-14 years | 11-12 years | 2 vs 2 doses |
| Influenza (flu) | Risk groups, 65+ and pregnancy | 6 months and older, every season | 1 vs 1 doses |
In the routine U.S. schedule but not France's: Varicella (chickenpox), Hepatitis A, COVID-19.
Why France's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 7.8 new cases per 100,000 people per year (2024). BCG is routine only in some regions. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 13.1 reported cases per million people (2025). Two-dose coverage is 93%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: not part of the WHO-reported universal schedule here. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | France | United States |
|---|---|---|
| BCG (TB) | 78% (2007, old estimate) | not reported |
| DTP dose 1 | 99% (2025) | 98% (2025) |
| DTP dose 3 | 96% (2025) | 94% (2025) |
| Measles dose 1 | 96% (2025) | 92% (2025) |
| Measles dose 2 | 93% (2025) | 95% (2025) |
| Polio (IPV series) | 96% (2025) | 93% (2025) |
| Hep B birth dose | not reported | 75% (2025) |
| Hep B dose 3 | 96% (2025) | 93% (2025) |
| Hib dose 3 | 96% (2025) | 92% (2025) |
| Pneumococcal (PCV) | 96% (2025) | 84% (2025) |
| Rotavirus (complete) | 44% (2025) | 77% (2025) |
| HPV dose 1, girls | 62% (2025) | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).
Other Europe countries
Denmark · Finland · Germany · Italy · Norway · Poland · Spain · Sweden · United Kingdom · all 31 countries